摘要
目的探讨匹多莫德治疗儿科呼吸系统反复感染患儿的临床疗效。方法本文选择我院儿科于2015年9月～2017年9月收治的378例患者随机分为观察组(n=189)和对照组(n=189)。两组均进行常规基础治疗,对照组采用布地奈德雾化吸入,观察组在对照组的基础上联合匹多莫德治疗。观察比较两组患儿临床疗效,退热、咳嗽、扁桃体肿大及肺部啰音等临床症状消失时间,再感染次数及再感染持续时间。结果观察组有效率为95.77%,明显高于对照组的81.48%,两组临床效果比较,差异有统计学意义(Z=-9.792,P=0.000)。观察组退热时间为(2.48±0.73)d,咳嗽消失时间(4.05±1.02)d,扁桃体肿大消失时间(2.89±0.97)d,肺部啰音消失时间(4.30±1.21)d,均明显低于对照组(t=-15.275,P=0.000;t=-18.686,P=0.000;t=-18.689,P=0.000;t=-17.903,P=0.000);观察组再感染次数(1.97±0.26)次,再感染持续时间(2.83±0.70)d,均明显低于对照组的(5.12±1.45)次和(7.69±2.04)d,差异有统计学意义(t=-29.397,P=0.000;t=-30.979,P=0.000)。结论匹多莫德治疗儿科呼吸系统反复感染临床疗效显著,可有效减少临床相关症状消失时间,降低再感染发生率,提高患儿免疫功能,值得推广应用。
Objective To investigate the clinical efficacy of pidotimod in the treatment of children with pediatric repeated respiratory infections. Methods A total of 378 patients admitted in the department of pediatrics of our hospital from September 2015 to September 2017 were randomly divided into the observation group(n=189) and the control group (n=189). Routine basic treatment was performed in both groups. The control group was inhaled with budesonide, and the observation group was treated with pidotimod on the basis of the treatment in the control group. The clinical efficacy, the time of disappearance of clinical symptoms such as fever, cough, tonsil enlargement and lung vocalization, the number of reinfections and the duration of reinfection between the two groups were observed and compared. Results The effective rate of the observation group was 95.77%, which was significantly higher than that of the control group (81.48%), the difference of the clinical effect between the two groups was statistically significant(Z=-9.792, P=0.000). The antipyretic time of the observation group was (2.48±0.73)d, the disappearance time of cough was (4.05±1.02)d, the disappearance time of tonsil enlargement was (2.89±0.97)d, and the disappearance time of lung arpeggio was (4.30±1.21d), which were significantly lower than those of the control group(t=-15.275,P=0.000;t=-18.686,P=0.000;t=-18.689,P=0.000;t=-17.903,P=0.000). The number of reinfections was (1.97±0.26), and the duration of reinfection was (2.83±0.70)d in the observation group, which was significantly lower than the(5.12±1.45) and (7.69±2.04)d of the control group (t=-29.397,P=0.000;t=-30.979,P=0.000). Conclusion Pidotimod has a significant clinical effect in the treatment of pediatric respiratory system repeated infections. It can effectively reduce the disappearance time of clinically relevant symptoms, reduce the incidence of reinfection, and improve the immune function of children. It is worthy of popularization and application.
作者
马明梅
吉桂芳
冶秀兰
MA Mingmei;JI Guifang;YE Xiulan(Vein Configuration Center, Affiliated Hospital of Qinghai University, Xi'ning 810000, China;Pharmacy Department, Affiliated Hospital of Qinghai University, Xi'ning 810000, China;Department of Pediatrics, Affiliated Hospital of Qinghai University, Xi'ning 810000, China)
出处
《中国现代医生》
2019年第8期105-107,111,共4页
China Modern Doctor
关键词
匹多莫德
儿科
呼吸系统反复感染
免疫功能
Pidotimod
Pediatrics
Repeated respiratory infection
Immune function
